R-Biopharm has inked an agreement with HMNC Brain Health for a diagnostic test to optimize the efficacy of depression treatment.
Under the agreement, R-Biopharm will create an in vitro test for detecting ABCB1 gene variants in patients taking antidepressants.
The agreement covers all development, regulatory, manufacturing and commercial activities related to thetest. Financial terms were not disclosed. — Anisa Jibrell